B
Biossil
Canada · Biotech
Biossil uses AI to identify and develop drug candidates that other companies have discontinued.
Product
Biossil acquires or licenses drug candidates with potential for further development, then combines AI analysis with clinical research to advance them. It focuses on serious diseases with unmet medical needs.
The Toronto-based biopharmaceutical company is building development infrastructure in Canada and the United States. Its work includes assessing existing research and expanding clinical programs.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity financing | $153M | OpenAI Startup Fund — Lead |